1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generic Drug

The Business of Generics: Market Trends & Strategies Explained

  • Currently 4/5 Stars.
  • 1
  • 2
  • 3
  • 4
  • 5
24 votes

Global Generic Drug Industry

The global generic drug market should grow at a compound annual growth rate of 15% over five years to be worth just under $169 billion in 2014, according to a report from BCC Research.

The generic drug industry (as a part of the pharmaceutical business) covers the marketing and sale of medication containing the same active ingredients and dosages as brand-name drugs manufactured by the pharmaceutical industry. Drugs can be prescribed under their chemical name without specifying a particular pharmaceutical brand or company. A key benefit of generic drugs is that they usually cost a fraction of the price of brand-name drugs, as much as 80% to 85% less according to the US Food and Drug Administration. For example, Glucotrol, a drug used in the treatment of diabetes, represents a monthly cost to patients of between $42 and $84 for 10 mg tablets; however, the drug’s generic version, Glipizide, costs up to 10 times less at between $4 and $8 per month.

Generic drugs are under the same governance as brand-name drugs and must adhere to the same standards. When brand-name drugs come off patent, the market is opened up to generic versions. Patent protection generally protects a drug’s intellectual property rights for about 20 years, but as the patent is effective from the clinical trial stage, the actual time the drug is on the market can be far less, often between 10 and 14 years. After a patent expires, pharmaceutical companies come under fierce pricing pressure due to competition from their less-expensive generic counterparts.

Drugs coming off patent through 2014 represent a forecast annual loss of $136 billion, according to industry analysis. Generics help reduce government spending on healthcare, accounting in part for a near 5% decrease in US drug spending, reports the FDA. The FDA acts as a governing body for generic drugs to enforce maximum standards of variation with brand-name drugs. However, in an 11-year study, variation in absorption of branded and generic drugs was found to be as little as 3.5%. Such negligible variation could equally exist in a comparison of two branded drugs.

Value of Products at risk to Generic Competition - 2010 to 2014 

Best-Selling Generic Drugs

Generic drugs took all of the top-10 spots for the most-prescribed drugs in the US last year, as ranked by the IMS Institute for Healthcare Informatics. Only three brand-name drugs ranked in the top 25, highlighting the strong foothold secured by generics.

Possibly further boosting future sales is the looming patent expiration of several of the pharmaceutical world’s star prescription brand-name drugs, for which generics are poised to claim sizeable market share. Top generic drugs to enter the market this year are expected to be Methylphenidate (an attention deficit hyperactivity disorder drug taking over from Concerta) and Levofloxacin (a copy of antibiotic Levaquin). In October 2011 Zyprexa, used to treat bipolar disorder and schizophrenia, will come off patent leaving the door open for generic Olanzapine. November 2011 will see a top selling drug in the US, Pfizer’s Lipitor used to treat cholesterol, come off patent; Lipitor represents annual profit from sales of $10 billion, reports the New York Times.

In March 2012, depression drug Lexapro will come off patent, leaving room for generic Escitalopram. In the same month generic Quetiapine will be poised to compete with antipsychotic Seroquel. Clopidogrel, used to prevent blood clots and ward off strokes and heart attacks, will be able to take some of Plavix’s market share.

Other generics set to take over from brand-name drugs include:

  • Fenofibrate based on the cholestrol drug Tricor
  • Montelukast based on the asthma and allergy treatment Singulair
  • Pioglitazone based on the diabetic drug Actos
  • Valsartan based on the high blood pressure medication Diovan

Industry Leaders

BCC Research shows Teva Pharmaceutical Industries to hold just under 20% of the global generic drugs market, followed by Sandoz, with 10% of the market. In joint third place are Watson and Mylan, with 6% each. Together, Teva, Sandoz, Watson and Mylan hold a combined 40% share of the global market.

Generic Drug Industry Trends

The generic drug market is gaining increasing ground over brand-name pharmaceuticals, with the FDA reporting that generics account for more than 70% of prescription drugs in the US. The US market for generic drugs is forecast to show more than 10% CAGR, reaching $54 billion in 2014. Japan is likely to see over 12% growth to exceed $9.5 billion in 2014, reports BCC Research.

Generic Drugs: Market Share Forecasts for Developed Markets to 2015

Read more »

24/7 Customer Support

Talk to Sam

+1 718 473 0872

1-10 of about 200 reports

Global Generic Drug Industry

  • May 2015
    11 pages
  • Generic Drug  

View report >

Generic Drug Industry in the US

  • September 2016
    9 pages
  • Generic Drug  

  • United States  

View report >

Generic Drug Statistics in Japan

  • March 2015
    5 pages
  • Generic Drug  

  • Japan  

View report >

Generic Drug Statistics in the UK

  • January 2015
    8 pages
  • Generic Drug  

  • United Kingdom  


View report >

Generic Drug Supply in Canada

  • October 2016
    26 pages
  • Generic Drug  


    Supply Chain  

  • Canada  

    North America  

View report >

Generic Drug Industry in Brazil

  • April 2016
    10 pages
  • Generic Drug  

  • Brazil  


View report >

Generic Drug Industry in India

  • November 2016
    7 pages
  • Generic Drug  


  • India  

View report >

Generic Drug Industry in China - Forecast

  • January 2016
    12 pages
  • Pharmaceutical  

    Generic Drug  

  • China  


View report >

Generic Drug Industry in Spain

  • June 2014
    6 pages
  • Generic Drug  

  • Spain  

View report >

Generic Drug Industry in Taiwan

  • January 2014
    36 pages
  • Generic Drug  

  • Taiwan  

View report >

Search in Generic Drug Industry (About 200 reports)
Parent industry: Pharmaceutical
Related industries: Drug Delivery, Drug Discovery and Development, OTC, Pharmacies and Drug Stores, Prescription Drug, Therapy

About 200 reports

Purchase Reports From Reputable Market Research Publishers
(From $ 500 - $ 2850)

Global Febuxostat Market Research Report 2016

Global Febuxostat Market Research Report 2016

  • $ 2850
  • Industry report
  • October 2016
  • by 9Dimen Research

2016 Global Febuxostat Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Febuxostat industry, focusing on the main regions (North America, ...

2016 Global And Chinese Gadobutrol (cas 138071-82-6) In ...

November 2016 $ 2800

2016 Global And Chinese Nicorandil Industry Market Rese ...

November 2016 $ 2800

2016 Global And Chinese Calcipotriol Industry Market Re ...

November 2016 $ 2800

2016 Global And Chinese Pyriproxyfen (cas 95737-68-1) I ...

November 2016 $ 2800

2016 Global And Chinese Nebivolol hydrochloride (cas 1 ...

November 2016 $ 2800

2016 Global And Chinese Gadopentetic Acid Industry Mark ...

November 2016 $ 2800

Global And Chinese Febuxostat Hcl (cas 144060-53-7) Ind ...

October 2016 $ 2800

Global And Chinese Tolterodine L-tartrate (cas 124937-5 ...

October 2016 $ 2800

Global And Chinese Prasugrel Impurity Industry, 2016 Ma ...

October 2016 $ 2800

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.